US OTC Monograph Facilty Fees Increase With Pandemic-Inspired Sanitizer Makers Exempted
Executive Summary
FDA publishes second notice on FY2021 rates for OTC monograph drug user fee program. With fewer firms paying, those still subject to facility fees will pay more so the total collected matches amount Congress authorized agency to collect, nearly $23.3m.
You may also be interested in...
US OTC Monograph FY2022 Facility Fees Deadline In June At Amount TBD
Firms making OTC monograph drugs won’t have to pay facility fees twice during FY2021, says Theresa Michele, FDA Office of Nonprescription Drugs director.
US FDA Meets Initial Deadlines In OTC Monograph Overhaul While It's Rebuilding The Program
Authorization was a long time coming for FDA to reform OTC monograph program and streamline process to change formulations, indications or labeling for large majority of drugs available nonprescription. As program is overhauled, monograph updates may seem to be coming just as slowly.
Florida Hand Sanitizer Firm’s Pandemic Experience: Recall Contaminated Product, Cease Production
Sanit Technologies must provide FDA with full reconciliation for all hand sanitizers not recalled and detailed plan of business closing. Warning letter notes its product’s risk to vulnerable populations and its distribution to schools with young children.